A biotech developing and commercializing cutting-edge vaccines utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor biology.Dynavax Technologies is focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.

Core values

- Dynavax is primarily focused on developing vaccines for infectious diseases, such as hepatitis B with its product Heplisav-B. This addresses a significant public health need by providing protection against serious and potentially life-threatening diseases[1][2].
- By developing and commercializing vaccines like Heplisav-B, Dynavax contributes to the prevention of diseases, which directly improves the quality of life for individuals and communities. Vaccines reduce the burden of illness, hospitalizations, and mortality rates, thereby enhancing overall public health[1][2].
- The company's commitment to adult immunization, especially highlighted during the COVID-19 pandemic, promotes a broader understanding and support for vaccination programs. This can lead to increased vaccination rates and better public health outcomes[5].
- Dynavax's efforts in maintaining its commercial team and engaging with health systems during the pandemic helped in building market share and ensuring that their vaccine was available when the market recovered. This continuity is crucial for community health and well-being[1].